^
    Back
    Association details:
    Biomarker:PIK3CA mutation + ER positive
    Cancer:HER2 Negative Breast Cancer
    Drug:Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) +
    Piqray (alpelisib) (PIK3CA inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Breast Cancer Res
    Title:

    Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer

    Published date:
    08/14/2020
    Excerpt:
    EFM19 and EFM19-PR cells show comparable sensitivity in vitro to alpelisib (p110α-selective PI3K inhibitor) single agent and combination with palbociclib (Fig. 2a).
    DOI:
    10.1186/s13058-020-01320-8